THI Professor Dr Alexander Schuhmacher was interviewed for Forbes Magazine

For nine years, Dr Alexander Schuhmacher, professor at Technische Hochschule Ingolstadt (THI), has been dealing with strategic issues of research and development (R&D) in the global pharmaceutical and biotech industry. To this end, he and Prof. Dr Oliver Gassmann (University of St. Gallen) have established a network in which experienced experts from industry and academia conduct joint research.

There are many working groups worldwide that deal with R&D management issues, but not many academic groups that have managed to conduct high-quality research on pharmaceutical R&D on a permanent basis and with a lot of influence, as Dr Alex Zhavoronkov, an expert on AI for healthcare and longevity biotechnology researched for Forbes Magazine. In fact, three research groups are leading the way worldwide, including the network to which Prof. Dr. Alexander Schuhmacher belongs.

For the renowned Forbes Magazine, one of the most successful business magazines worldwide, Zhavoronkov interviewed Prof. Dr. Alexander Schuhmacher and Prof. Dr. Oliver Grassmann as two of the world's most influential researchers in this field. The question is why the pharmaceutical industry invests around 150 billion US dollars a year in researching new drugs and why, on average, only 30 to 40 new active substances are usually approved each year. "We, as a neutral group, try to explain the causes and background of this and develop strategies for what the industry needs to do to become more efficient," explains Prof. Dr. Alexander Schuhmacher.

The article consists of two parts. It can be found at: www.forbes.com/sites/alexzhavoronkov/2022/04/11/over-10000-diseases-and-only-50-drugs-approved-in-2021-to-improve-pharma-rd-efficiency-we-need-to-understand-it/

As well as at: www.forbes.com/sites/alexzhavoronkov/2022/04/18/what-are-the-most-productive-pharmaceutical-companiespharmaceutical-rd-efficiency-review-1999-2018/